Mannomustine

Mannomustine (INN), also known as mannitol nitrogen mustard, tradename Degranol is an old alkylating antineoplastic agent from the group of nitrogen mustards. It was first synthesized and characterized in 1957 by Vargha et al.[1]

Mannomustine
Clinical data
Trade namesDegranol
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
    Routes of
    administration
    Intramuscular
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    MetabolismHepatic
    ExcretionRenal
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC10H24Cl4N2O4
    Molar mass378.11 g·mol−1
    3D model (JSmol)

    The mechanism of antineoplastic activity of mannomustine, like for all other alkylating agents, lies in its ability to alkylate DNA guanine nucleobases and, thus, to prevent uncoupling of DNA strands, which is a required step for any cell to divide.

    Mannomustine was, at the time of its creation as a drug, claimed to be considerably less toxic than mechlorethamine. For example, the LD50 in rats, for intravenous mannomustine administration route, is claimed to be about 56 mg/kg.[2]

    See also

    References

    1. Vargha et al., J. Chem. Soc. 1957, 805.
    2. Scherf et al., Arzneim.-Forsch. 20, 1467 (1970)
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.